Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Filament Health Corp (OP: FLHLF )

0.0165 -0.0005 (-2.94%)
Streaming Delayed Price Updated: 10:46 AM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Filament Health Corp

< Previous 1 2 3 Next >
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Via Benzinga
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
Via Benzinga
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
Via Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Via Benzinga
'Rainforests Are Nature's Medicine Cabinets': Biotech Co. Performs Fresh Research On Traditional Plants For Modern Mental Health Challenges
Via Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
Via Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also... 
Via Benzinga
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
Exposures Interest Rates
Peru's Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details
Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF) 
Via Benzinga
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Starting this October, scientists at Imperial College London’s (ICL) Centre for Psychedelic Research will assess psilocybin-assisted therapy for gambling addiction, noted Psychedelic Spotlight. 
Via Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Filament Health Shares Q1 2023 Financials, Material Uncertainties Upon Securing Additional Financing
Natural psychedelic drug development company Filament Health (OTCQB: FLHLF) has released its unaudited consolidated, condensed financial results for Q1 2023 ended June 30. Numbers show: 
Via Benzinga
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... 
Via Benzinga
Filament Health Uplisting To NASDAQ In A $210M SPAC Deal
Canadian clinical-stage natural psychedelics company Filament Health (OTCQB: FLHLF)  has entered into a definitive agreement with Jupiter Acquisition Corp. (NASDAQ: JAQC), a Special Purpose Acquisition... 
Via Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic... 
Via Benzinga
Filament Supplies Botanical Psilocybin To Canadian Researchers, Inks Global Licensing Deal
Clinical-stage natural psychedelics company Filament Health (OTCQB: FLHLF) will supply psilocybin for two clinical studies funded by the Canadian Institutes of Health Research (CIHR) operating grants... 
Via Benzinga
UCSF Clinical Trial Shows Promising Results For Naturally-Sourced Psilocybin And Psilocin
A Phase 1 clinical trial led by the University of California San Francisco (UCSF) assessing research partner Filament Health Corp.’s (OTCQB: FLHLF) botanical psychedelic drug candidates has shown... 
Via Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
African Iboga Root Heads To Canadian Company Developing Natural Drugs To Help Treat Addictions
Clinical-stage natural psychedelics company Filament Health Corp. (OTCQB: FLHLF) has completed the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to the company’s R&D... 
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Filament Health's Q1 2023 Financial Results, Material Uncertainty On The Horizon
Natural psychedelics drug developer Filament Health Corp. (OTCQB: FLHLF) shared its interim financial results and further business highlights for the first quarter ended March 31, 2023. 
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
Two Psychedelics Companies Collaborate To Provide Clinical-Grade MDMA Capsules For Authorized Patients And Studies
MDXX-class molecules producer PharmAla Biotech Holdings Inc. 
Via Benzinga
Filament Health: 2022 Financials And Operational Highlights From Creator Of The Ayahuasca Pill
The natural psychedelics company responsible for creating the first standardized ayahuasca capsule, Filament Health Corp. 
Via Benzinga
Psychedelic Research Expands In Australia With Palliative Care Partnership & New MDMA Analog Portfolio
Psyence Partners with iNGENū for Palliative Care Clinical Trial 
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Three companies have provided updates on their efforts to assess different psychedelics for treating a widely varied set of conditions. 
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
[Video] Revolutionizing Mental Health: Filament Health CEO Discusses The Future Of Psychedelic Medicine
Cannabis enthusiasts and industry insiders alike will find the latest episode of Benzinga's Cannabis Insider show both informative and engaging. 
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.